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c-erbB-3 protein expression in ovarian tumours
BJB Simpson', J Weatherill', EP Miller', AM Lessells2, SP Langdon' and WR Miller'
'ICRF Medical Oncology Unit and 2Department of Pathology, Western General Hospitals NHS Trust, Edinburgh EH4 2XU, UK.
Summary In this study the expression of c-erbB-3 protein was investigated in a range of human ovarian
tumours using a monoclonal antibody (RTJ1) raised to a synthetic peptide from the cytoplasmic domain of
the human c-erbB-3 protein. A total of 73 samples from 71 patients were graded as negative, weak, moderate
or strong according to the intensity of immunohistochemical staining observed, and this was related to tumour
characteristics and other clinical parameters. In terms of positivity vs negativity, of the 73 samples examined,
62 (85%) showed positive immunohistochemical staining for c-erbB-3. The majority of all ovarian tumours
studied were positive for c-erbB-3 regardless of whether they were malignant (89%), borderline (100%) or
benign (61%), however the incidence of positivity was significantly less in the benign group than in overtly
malignant tumours (P = 0.03). c-erbB-3 positivity was not significantly associated with either age at diagnosis,
tumour stage, differentiation, ploidy, percentage in S-phase or post-operative tumour bulk in malignant
tumours. In terms of intensity of staining no significant difference was observed either within the common
epithelial group or between this group and tumours of a benign nature. A significantly more intense pattern of
c-erbB-3 staining was observed in tumours of borderline malignancy when compared with their overtly
malignant counterparts (P = 0.002). Patients presenting with early-stage malignant tumours (I/II) were more
likely to display intense tumour staining than those with late-stage disease (III/IV) (P = 0.04). These investiga-
tions suggest that c-erbB-3 protein is frequently expressed in both benign and malignant ovarian tumours, and
that overexpression is more common in borderline and early invasive lesions.
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Abnormal expression of a number of growth factors and
their receptors has been linked with prognosis and disease
outcome in many diverse tumour types, including ovarian
cancer (Berns et al., 1992; Kohler et al., 1992; Bauknecht et
al., 1993). Gene amplification and protein overexpression of
receptor tyrosine kinases including the epidermal growth fac-
tor receptor (EGFR) and c-erbB-2 protein have been
associated with the induction and progression of a number of
human cancers (Sainsbury et al., 1987; Bauknecht et al.,
1988; Gullick et al., 1988; Slamon et al., 1989; Berchuck et
al., 1990, 1991; Scambia et al., 1992). A relatively new
member of this type I growth factor receptor family, c-erbB-
3, has also been characterised (Kraus et al., 1989; Plowman
et al., 1990), although clarification of its biological role
awaits identification of a specific ligand.
c-erbB-3 protein has been found in normal human adult
and fetal tissues, including the ovary (Prigent et al., 1992),
and has also been shown to be expressed at both the mRNA
and protein levels in a number of tumour cell lines and
primary tumour material (Lemoine et al., 1992; Rajkumar et
al., 1993). Rajkumar et al. (1993) have described the produc-
tion of a monoclonal antibody (RTJI) which is specific for
c-erbB-3 protein, and using this antibody they have reported
positive immunohistochemical staining for c-erbB-3 protein
of varying intensities in a series of tumours from the gas-
trointestinal tract.
c-erbB-3 gene expression has been shown to be elevated in
ovarian carcinomas (Mandai et al., 1994), however to date
there have been no reports of the presence of c-erbB-3 pro-
tein in ovarian cancer. In this study we have used the RTJ1
monoclonal antibody to detect c-erbB-3 protein by immuno-
histochemistry in a cohort of ovarian tumours, and this was
related to tumour characteristics and a number of related
clinical parameters.
Materials and methods
Patients
Tissue samples were collected at initial debulking surgery for
suspected ovarian malignancy. In the current study ovarian
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material was obtained from 71 patients with a median age of
60.5 years (range 26-90). Two normal ovaries were collected
from premenopausal patients, both of whom were 43 years of
age. Upon collection the samples were stored in liquid nitro-
gen and subsequently were formalin fixed and paraffin
embedded.
Immunohistochemistry
A standard avidin-biotin complex method was used to
locate c-erbB-3 protein. Briefly, following deparaffinisation
and endogenous peroxidase blocking, 3 ym sections were
washed in 0.05 M Tris-HCI buffer (pH 7.6) and subjected to
proteolytic digestion in 0.1% trypsin/calcium chloride at
37°C for 20 min. The sections were subsequently washed in
Tris-HCI, blocked with 1% non-fat milk protein (Marvel)
for 20 min at .room temperature to reduce non-specific back-
ground staining and incubated with the monoclonal antibody
RTJ1. This antibody (kindly donated by Professor WJ Gul-
lick), raised to a synthetic peptide from the cytoplasmic
domain of the human c-erbB-3 protein (Rajkumar et al.,
1993), was used at a dilution of 1:20 and incubated at room
temperature for 1 h. Following antibody incubation, the sec-
tions were washed thoroughly in Tris-HCI buffer before
incubation with biotinylated rabbit anti-mouse immuno-
globulins (Dako) for 30 min at room temperature, followed
by another Tris-HCI wash. The sections were further
incubated for 30 min at room temperature following the
addition of an avidin-biotinylated horseradish peroxidase
complex (Dako). Sections were again washed in Tris-HCI
and bound antibody visualised with 3,3'-diaminobenzidine
tetrachloride (Sigma). Finally, the sections were washed in
running tap water and stained with haematoxylin.
Positive control slides were included in every run. Normal
kidney showed both proximal and distal convoluted tubules
staining with the RTJ1 antibody, with distal tubules staining
more strongly. Negative controls in which the primary
antibody was replaced by Tris-HCI buffer were also included
with every run.
Following staining procedures, all samples were examined
by two observers independently, and scored as negative,
weak, moderate or strong depending upon the staining inten-
sity observed. Tumours which showed heterogeneous staining
patterns were scored as positive irrespective of the number of
positively stained cells.
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Pathology
Tumour pathology, as obtained from patient records, was
confirmed on haematoxylin and eosin-stained sections.
Tumours were classified as either malignant, borderline (low
malignant potential) or benign and assigned a histological
type.
Clinical information
Patients' age at diagnosis, tumour stage (FIGO), tumour
differentiation and post-operative tumour bulk were re-
corded. Accurate information on menopausal status was not
available for all patients involved in this study. Patients were
therefore divided into two groups according to age: those less
than and those greater than 50 years at the time of diagnosis.
Tumour stage was also categorised into two groups: early
stage, comprising patients presenting with ovarian cancer at
stages I and II, and late stage, i.e. those presenting with
disease at stages III and IV. Well- and moderately
differentiated tumours were considered as a single group
because of the small number of tumours in each of these two
categories, and were compared with those of poor differen-
tiation. Post-operative tumour bulk was assessed by deter-
mining the greatest diameter of the residual disease; less than
2 cm was classified as debulked and greater than 5 cm as not
debulked.
DNA flow cytometry
Cells were treated with trypsin/detergent and the DNA
stained with propidium iodide (Vindelov et al., 1983).
Analysis was performed using FACScan flow cytometer (Bec-
ton Dickinson) equipped for doublet discrimination using
Cellfit software. All data were gated on forward- and side-
scatter signals to exclude fragmented and clumped material,
and on a fluorescence width vs fluorescence area signal to
exclude doublets.
DNA profiles were evaluated, and those showing a single
GO/'G peak were classified as DNA diploid, whereas DNA
profiles showing one or more additional GO/GI peaks were
classified as DNA aneuploid. The degree of aneuploidy was
expressed as the DNA index. A measure of the percentage of
cells in S-phase was taken as an estimate of tumour pro-
liferative activity.
Statistics
Relationships between variables were analysed using the
Mann-Whitney U-test and Kruskal-Wallis non-parametric
test. Comparisons between c-erbB-3-positive and -negative
tumours were analysed by Fisher's exact tests.
Results
Cohort analysis
A total of 73 samples from 71 patients (bilateral tumours
collected from two patients) were analysed by immunohis-
tochemistry to determine the presence of c-erbB-3 protein.
Pathological analysis revealed this cohort to consist of 52
malignant, eight borderline/low malignant potential (of which
five were mucinous and three serous) and 13 benign tumours
(four mucinous cystadenomas, one serous cystadenofibroma,
one mucinous cystadenofibroma, two fibromas, two theco-
fibromas, two mature cystic teratomas and one Brenner). Of
the malignant group, 46 tumours were of common epithelial
origin and six were described as being of mixed origin. The
mixed origin group comprised two tumours of mixed
epithelial origin, three of mixed mesodermal origin and one
sex cord stromal tumour. Patient details and tumour charac-
teristics are outlined in Table I.
c-erbB-3 immunohistochemistry
Of the 73 samples examined, 62 (85%) were positive for
c-erbB-3, and of these 45% showed weak, 39% moderate and
a
b
Figure 1 (a) Immunoreactivity for c-erbB-3 protein in an
endometrioid ovarian tumour showing a typical pattern of
homogeneous cytoplasmic staining. (b) A rare example of
membrane-associated c-erbB-3 staining in a mucinous cys-
tadenoma.
Table I Ovarian tumour pathology and other clinically related parameters
Age Stage Differentiation Bulk
Pathology No. <50 >50 I II III IV Well Moderate Poor Unknown db pdb ndb Unknown
Serous 22 6 16 1 1 18 2 0 2 20 0 9 8 5 0
Endometrioid 16 2 14 7 2 6 1 1 8 7 0 1 1 1 1 3
Clear cell 6 0 6 5 0 1 0 0 5 1 0 .6 0 0 0
Mucinous 1 0 1 1 0 0 0 0 1 0 0 1 0 0 0
Mixed origin 6 0 6 2 2 2 0 0 2 3 1 6 0 0 0
Borderline 7 6 1 7 0 0 0 - - - - 7 0 0 0
Benign 13 2 1 1 - - - - - - - - 10 0 1 2
No. = number of patients in each group. Stage = FIGO classification. Bulk = bulk of residual disease following primary operation: db,
debulked; pdb, partially debulked; ndb, not debulked. Unknown = patients lost to follow-.up.
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16% strong staining intensity patterns. Typically tumour cells
showed an homogeneous pattern of cytoplasmic staining for
c-erbB-3 irrespective of phenotype or histology, with no
staining of the stromal tissue and only occasional membrane-
associated staining observed (Figure 1). In both of the nor-
mal premenopausal ovaries studied the surface epithelial
cells, from which common epithelial malignancies are
thought to originate, did not show positivity for c-erbB-3.
Positive staining was observed in granulosa cells of cystic
follicles and corpora lutea and in luteinised cells scattered
within the stroma (data not shown).
Tumour pathology
Most tumours studied showed positive staining for c-erbB-3
irrespective of their pathology (Table II). In the malignant
common epithelial tumour group, 91% of serous, 87.5% of
endometrioid, 83.3% of clear cell tumours and one mucinous
tumour examined were positive for c-erbB-3. Similarly, the
majority of malignant ovarian tumours of mixed origin and
those classified as borderline/low malignant potential showed
extensive positive staining for c-erbB-3 (83.3% and 100%
respectively, Table II), and the incidence of positivity was not
significantly different from the malignant common epithelial
group. Most benign tumours (61.5%) also showed positive
immunohistochemical staining for c-erbB-3, however the
incidence of positivity was significantly less than that in
malignant tumours of common epithelial origin (P = 0.03).
Variable staining intensity for c-erbB-3 was observed
across the ovarian tumour groups. There was, however, no
significant difference in the staining intensity patterns
observed either within the malignant common epithelial
group (P = 0.30) or between this group and those of benign
nature (P = 0.50). However, tumours of borderline malig-
nancy showed a significantly greater degree of staining inten-
sity than those of the malignant common epithelial group
(P = 0.002), and indeed all eight borderline tumours dis-
played moderate or intense staining.
Clinical and other tumour parameters in malignant common
epithelial tumours
Within the malignant common epithelial group there were no
significant differences in incidence of tumour positivity for
c-erbB-3 when the patients were subdivided according to age
at diagnosis, tumour stage, differentiation, ploidy, percentage
in S-phase and the extent of residual disease following
debulking surgery (Table III). Similarly, no significant
differences were observed in the degree of staining intensity
when tumours were classified by these same parameters,
except for stage, patients presenting with early-stage tumours
showing significantly more intense staining patterns for c-
erbB-3 protein than those presenting with late-stage disease
(P = 0.04, Table III).
Table II Tumour pathology and pattern of c-erbB-3 staining as determined by
immunohistochemistry
c-erbB-3 staining intensity
Tumour pathology No. Negative Weak Moderate Strong
Common epithelial
Serous 23 2 15 5 1
Endometrioid 16 2 5 5 4
Clear cell 6 1 1 4 0
Mucinous 1 0 1 0 0
Borderline
Serous 3 0 0 2 1
Mucinous 5 0 0 2 3
Mixed origin
Mixed epithelial 2 1 0 1 0
Mixed mesodermal 3 0 3 0 0
Sex cord stromal 1 0 1 0 0
Benign
Mucinous cystadenoma 4 2 0 1 1
Serous cystadenofibroma I 1 0 0 0
Mucinous cystadenofibroma 1 0 0 1 0
Fibroma 2 2 0 0 0
Thecofibroma 2 0 2 0 0
Mature cystic teratoma 2 0 0 2 0
Brenner 1 0 0 1 0
Total 73 11 28 24 10
Table III c-erbB-3 staining and its relationship with tumour and clinical parameters in common
epithelial ovarian malignancies
c-erbB-3 c-erbB-3 intensity
No. + ve + ve P-value Weak Moderate Strong P-value
Age<50 years 9 8 1 3 3 2
Age> 50 years 38 34 4 1.00 19 12 3 0.56
Stage I/II 17 17 0 6 9 2
Stage III/IV 29 24 5 0.14 15 6 3 0.04
Well/moderate 17 15 2 1.00 8 6 1 0.82
Poor 29 26 3 14 8 4
Diploid 9 8 1 5 2 1
Aneuploid 36 32 4 1.00 16 12 0.70
db 28 25 3 1.0I1 12 2 03
ndb/pdb 15 13 2 1.00 9 2 2 0.35
c-erbB-3 + ve vs -ve: Fisher's exact test. Staining intensity: Mann-Whitney test. No. = number
of patients in each group. Stage = FIGO classification. bulk = bulk of residual disease following
primary operation: db, debulked, ndb, not debulked, pdb, partially debulked.
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Discussion
There has been considerable interest in the role of the c-erbB
family of growth factor receptors in cancer development and
progression. Both c-erbB-1 (EGFR) and c-erbB-2 overexpres-
sion have been associated with aggressive behaviour in a
series of solid tumours, including breast (Sainsbury et al.,
1987; Slamon et al., 1989), cervix (Gullick et al., 1988;
Pfeiffer et al., 1989) and ovary (Bauknecht et al., 1988;
Berchuck et al., 1990; Scambia et al., 1992). In contrast,
considerably less is known about the involvement of c-erbB-3
in malignancy. Although c-erbB-3 has been reported to be
present in certain cancers, to our knowledge the present
report represents the first substantial study of c-erbB-3 pro-
tein expression in human ovarian tumours.
Using immunohistochemical techniques with the RTJ1
monoclonal antibody, we were able to detect staining in most
but not all ovarian tumours, irrespective of whether they
were histologically benign or malignant. Staining for c-erbB-3
is therefore not a marker of malignancy in ovarian tumours,
although there was a significant trend for cancers to be more
likely to display c-erbB-3 positivity. Similarly, the degree of
staining intensity for c-erbB-3 was not significantly different
between benign and malignant tumours. However, it was
noticeable that all borderline malignancies were positive for
c-erbB-3, the degree of staining being significantly more
intense in these borderline malignancies than in either benign
or overtly malignant tumours. Among unequivocally malig-
nant tumours, those of early stage displayed significantly
increased staining intensity as compared with tumours of a
later stage. These observations suggest that c-erbB-3 may be
up-regulated during the preinvasive and early stages of malig-
nancy in ovarian cancer. Interestingly, However, we were able
to confirm the finding of Prigent et al. (1992) that surface
epithelial cells of the normal ovary, from which common
epithelial ovarian tumours are thought to originate, did not
show positivity for c-erbB-3. It may be relevant that a similar
situation is apparent for c-erbB-2 in breast cancer in which
the expression of c-erbB-2 in intraduct and early invasive
lesions is greater than that observed in breast cancer display-
ing the full malignant phenotype (Barnes et al., 1991; Allred
et al., 1992). In pure ductal carcinoma in situ c-erbB-2
positivity appears to be associated with a subset of tumours
with greater invasive potential (Barnes et al., 1992). As far as
we are aware similar data for c-erbB-3 in breast cancer have
not been reported.
Apart from increased expression among borderline and
early-stage lesions, no significant correlations between c-erbB-
3 and tumour features and clinical parameters such as
tumour histology, differentiation, nuclear ploidy, S-phase,
patient age and extent of debulking surgery were observed.
While we continue to accrue survival data, insufficient events
have occurred so far to allow for any meaningful analysis,
and thus it would be premature to comment upon the poten-
tial prognostic significance of c-erbB-3. In breast cancer,
however, overexpression of c-erbB-3 appears not to correlate
with disease outcome, but is associated with the presence of
lymph node metastases in these patients (Lemoine et al.,
1992). Furthermore, the genesis and progression of ovarian
cancer will probably need to be assessed in combination with
other members of the c-erbB family and coexpression of their
potential ligands. Results of such studies are awaited with
great interest, especially in the case of ovarian cancer for
which there are no reliable biological predictors of outcome.
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